Innovent Signs US$1.1B Licensing Alliance with Spero for IBI355 (SP001), for the Teatment Immune-Mediated Diseases
By Naini Anand
Pharma Deals Review: Vol 2026 Issue 8 (Table of Contents)
Published: 5 Aug-2026
DOI: 10.3833/pdr.v2026.i8.3031 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Innovent Biologics and Spero Therapeutics have entered into a global license agreement for IBI355 (SP001), a third-generation Fc-silent anti-CD40L antibody...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.
RSS